摘要
Abstract
AIM To analyze the occurrence and clinical characteristics of adverse reactions(ADR)caused by evolocumab and alirocumab,to provide a basis for promoting rational clinical medication.METHODS Case literature on ADR caused by evolocumab and alirocumab was screened and analyzed by searching CNKI databases,Wanfang databases,VIP databases,PubMed,and Web of Science from July 2015 to February 2024.The extracted data included patient sex,age,primary diseases and comorbidities,administration details(dosage and regimen)of evolocumab/alirocumab,type of ADR,time to ADR onset,management of ADR,and patient outcomes.RESULTS A total of 16 literature reports on ADR were retrieved,with 17 patients included.Patients had a mean age of 61.9±15.2 years,with ages ranging from 28 to 81 years.The age group with the highest proportion was 61-90 years,accounting for 70.6％.Comorbidities were present in 11 patients(64.7％),and concomitant medications(all indicated for chronic conditions)were used in 7 patients(41.2％).The route of administration,indications,and dosages of the implicated drugs were consistent with prescribing information.The occurrence of ADR mainly occurred within 1-15 days(52.9％),mainly involving skin and soft tissue,respiratory system disorders and systemic damage.ADR resolved or improved following drug discontinuation or symptomatic treatment in 16 patients;one patient died due to recurrent infection after aortic implantation,unrelated to the ADR.CONCLUSION During clinical use of evolocumab and alirocumab,close monitoring for ADR is essential,especially in elderly patients.Timely discontinuation and management should be ensured upon occurrence to enhance patients'medication safety.关键词
依洛尤单抗/阿利西尤单抗/不良反应/文献分析Key words
evolocumab/alirocumab/adverse reactions/literature analysis分类
药学
